Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols

Abstract

In all, 134 elderly patients (median age 66 years, range 60–75 years) with newly diagnosed acute promyelocytic leukemia (APL) were enrolled in two successive protocols of the Italian multicenter group GIMEMA. All patients received an identical induction with all-trans retinoic acid and idarubicin; 116 (86%) entered complete remission (CR), two (2%) were resistant and 16 (12%) died during induction. After CR, 106 patients received further therapy whereas 10 did not, because of refusal (n=5) or toxicity (n=5). Consolidation consisted of three chemotherapy courses in the AIDA protocol (AIDA, 67 patients) or, since 1997, of an amended protocol including only the first cycle (amended AIDA, aAIDA, 39 patients). In the AIDA group, 43 patients (64%) completed consolidation, while seven (11%) and 17 (25%) patients were withdrawn after first and second courses, respectively; nine patients (13%) died in CR and 12 (18%) relapsed. In the aAIDA group, all patients received the assigned treatment; two patients (5%) died in CR and six (15%) relapsed. In the AIDA and aAIDA series, the 3-year overall and discase-free survival rates were 81 and 83% (P=NS), 73 and 72% (P=NS), respectively. We highlight here the frequency and severity of complications linked to intensive chemotherapy in this clinical setting and suggest that, in APL of the elderly, less intensive postremission therapy allows significant reduction of severe treatment-related toxicity and may be equally effective.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Warrell Jr RP . Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med 1996; 47: 555–565.

    Article  CAS  PubMed  Google Scholar 

  2. Frankel SR, Powell BL . Current approaches to acute promyelocytic leukemia. In: Tallman MS, Gordon LI (eds). Diagnostic and Therapeutic Advances in Hematologic Malignancies. Boston: Kluwer Academic Publishers, 1999, pp 125–153.

    Chapter  Google Scholar 

  3. Degos L, Wang ZY . All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001; 20: 7140–7145.

    Article  CAS  PubMed  Google Scholar 

  4. Tallman MS, Nabhan C, Feusner JH, Rowe JM . Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.

    Article  CAS  PubMed  Google Scholar 

  5. Avvisati G, Mele A, Stazi MA, Vegna ML, Pasquini P, Mandelli F . Epidemiology of acute promyelocytic leukemia in Italy. Ann Oncol 1991; 2: 405–408.

    Article  CAS  PubMed  Google Scholar 

  6. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M . Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–490.

    Article  CAS  PubMed  Google Scholar 

  7. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.

    CAS  PubMed  Google Scholar 

  8. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021–1028.

    Article  CAS  PubMed  Google Scholar 

  9. Soignet S, Fleischauer A, Polyak T, Heller G, Warrell Jr RP . All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997; 40(Suppl): S25–S29.

    Article  PubMed  Google Scholar 

  10. Asou N, Adachi K, Tamura J, Kanamaru A, Kagayama S, Hiraoka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78–85.

    Article  CAS  PubMed  Google Scholar 

  11. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131–4143.

    CAS  PubMed  Google Scholar 

  12. Sanz MA, Martin G, Rayon C, Esteve J, Gonzales M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia. Blood 1999; 94: 3015–3021.

    CAS  PubMed  Google Scholar 

  13. Wang Z, Sun G, Shen Z, Chen S, Chen Z . Differentiation therapy for acute promyeloctyc leukemia with all-trans retinoid acid: 10-year experience of its application. Chin Med J 1999; 112: 963–967.

    CAS  PubMed  Google Scholar 

  14. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192–1200.

    CAS  PubMed  Google Scholar 

  15. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362–1370.

    Article  CAS  PubMed  Google Scholar 

  16. Latagliata R, Avvisati G, Lo Coco F, Petti MC, Diverio D, Spadea A et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years. Ann Oncol 1997; 8: 1273–1275.

    Article  CAS  PubMed  Google Scholar 

  17. Latagliata R, Petti MC, Mandelli F . Acute myeloid leukemia in the elderly: ‘per aspera ad astra’? Leukamia Res 1999; 84: 814–819.

    Google Scholar 

  18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British cooperative group. Ann Intern Med 1985; 103: 620–625.

    Article  CAS  PubMed  Google Scholar 

  19. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229.

    CAS  PubMed  Google Scholar 

  20. Chomczynsky P, Sacchi N . Single step method of RNA isolation by acid guanidium thiocyanate–phenol chloroform extraction. Ann Biochem 1987; 162: 156–159.

    Google Scholar 

  21. Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F et al. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10: 1214–1216.

    CAS  PubMed  Google Scholar 

  22. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  23. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.

    CAS  PubMed  Google Scholar 

  24. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247–1253.

    CAS  PubMed  Google Scholar 

  25. Visani G, Buonamici S, Malagola M, Isidori A, Piccaluga PP, Martinelli G et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia 2001; 15: 1696–1700.

    Article  CAS  PubMed  Google Scholar 

  26. Douer D, Estey E, Santillana S, Bennet JM, Lopez-Bernstein G, Boehm K et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 2001; 97: 73–80.

    Article  CAS  PubMed  Google Scholar 

  27. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH et al. Experience with gemtuzumab ozogamycin (‘mylotarg’) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222–4224.

    Article  CAS  PubMed  Google Scholar 

  28. Dombret H, Fenaux P, Soignet SL, Tallman MS . Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39(Suppl 1): 8–13.

    Article  CAS  PubMed  Google Scholar 

  29. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M et al. Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822–824.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from Associazione Italiana contro le Leucemie (AIL), Ministero della Università e della Ricerca (MIUR) and Ministero della Salute.

Author information

Authors and Affiliations

Authors

Consortia

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mandelli, F., Latagliata, R., Avvisati, G. et al. Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17, 1085–1090 (2003). https://doi.org/10.1038/sj.leu.2402932

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402932

Keywords

This article is cited by

Search

Quick links